- Home
- IMSR vs HROW Comparison
IMSR vs HROW Comparison
Compare IMSR & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMSR
- HROW
- Stock Information
- Founded
- IMSR 2013
- HROW 1998
- Country
- IMSR United States
- HROW United States
- Employees
- IMSR N/A
- HROW N/A
- Industry
- IMSR
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- IMSR
- HROW Health Care
- Exchange
- IMSR Nasdaq
- HROW Nasdaq
- Market Cap
- IMSR 1.7B
- HROW 1.4B
- IPO Year
- IMSR N/A
- HROW N/A
- Fundamental
- Price
- IMSR $15.48
- HROW $35.59
- Analyst Decision
- IMSR
- HROW Strong Buy
- Analyst Count
- IMSR 0
- HROW 7
- Target Price
- IMSR N/A
- HROW $68.50
- AVG Volume (30 Days)
- IMSR 2.0M
- HROW 693.2K
- Earning Date
- IMSR 01-01-0001
- HROW 11-10-2025
- Dividend Yield
- IMSR N/A
- HROW N/A
- EPS Growth
- IMSR N/A
- HROW N/A
- EPS
- IMSR N/A
- HROW N/A
- Revenue
- IMSR $123,320.00
- HROW $227,661,000.00
- Revenue This Year
- IMSR N/A
- HROW $43.92
- Revenue Next Year
- IMSR N/A
- HROW $41.22
- P/E Ratio
- IMSR N/A
- HROW N/A
- Revenue Growth
- IMSR 1234.25
- HROW 47.69
- 52 Week Low
- IMSR $13.55
- HROW $20.85
- 52 Week High
- IMSR $21.00
- HROW $54.19
- Technical
- Relative Strength Index (RSI)
- IMSR N/A
- HROW 36.60
- Support Level
- IMSR N/A
- HROW $36.20
- Resistance Level
- IMSR N/A
- HROW $38.52
- Average True Range (ATR)
- IMSR 0.00
- HROW 1.78
- MACD
- IMSR 0.00
- HROW -0.36
- Stochastic Oscillator
- IMSR 0.00
- HROW 11.58
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.